Overview

A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).

Status:
Completed

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

This is a research study of an investigational drug called ambrisentan (Letairis) in the treatment and prevention of digital ulcers in patients with systemic sclerosis.

Phase:

N/A

Details

Lead Sponsor:

Stanford University

Treatments:

Ambrisentan